{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:46:05Z","timestamp":1794861965467,"version":"4.9.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Synaptic dysfunction is an early core feature of Alzheimer\u2019s disease (AD), closely associated with cognitive symptoms. Neuregulin 1 (NRG1) is a growth and differentiation factor with a key role in the development and maintenance of synaptic transmission. Previous reports have shown that changes in cerebrospinal fluid (CSF) NRG1 concentration are associated with cognitive status and biomarker evidence of AD pathology. Plasma biomarkers reflecting synaptic impairment would be of great clinical interest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To measure plasma NRG1 concentration in AD patients in comparison with other neurodegenerative disorders and neurological controls (NC) and to study its association with cerebrospinal fluid (CSF) core AD and synaptic biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study enrolled 127 participants including patients with AD at mild cognitive impairment stage (AD-MCI,\n                      <jats:italic>n<\/jats:italic>\n                      = 27) and at dementia stage (\n                      <jats:italic>n<\/jats:italic>\n                      = 35), non-AD dementia (\n                      <jats:italic>n<\/jats:italic>\n                      = 26, A\u03b2-negative), non-AD MCI (\n                      <jats:italic>n<\/jats:italic>\n                      = 19), and neurological controls (\n                      <jats:italic>n<\/jats:italic>\n                      =20). Plasma and CSF NRG1, as well as CSF core AD biomarkers (A\u03b2 42\/A\u03b2 40 ratio, phospho-tau, and total tau), were measured using ELISA. CSF synaptic markers were measured using ELISA for GAP-43 and neurogranin and through immunoprecipitation mass spectrometry for SNAP-25.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Plasma NRG1 concentration was higher in AD-MCI and AD dementia patients compared with neurological controls (respectively\n                      <jats:italic>P =<\/jats:italic>\n                      0.005 and\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). Plasma NRG1 differentiated AD MCI patients from neurological controls with an area under the curve of 88.3%, and AD dementia patients from NC with an area under the curve of 87.3%. Plasma NRG1 correlated with CSF NRG1 (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      = 0.372,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0056, adjusted on age and sex). Plasma NRG1 was associated with AD CSF core biomarkers in the whole cohort and in A\u03b2-positive patients (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      = \u22120.197\u20130.423). Plasma NRG1 correlated with CSF GAP-43, neurogranin, and SNAP-25 (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      = 0.278\u20130.355). Plasma NRG1 concentration correlated inversely with MMSE in the whole cohort and in A\u03b2-positive patients (all,\n                      <jats:italic>\u03b2<\/jats:italic>\n                      = \u22120.188,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.038; A\u03b2+:\n                      <jats:italic>\u03b2<\/jats:italic>\n                      = \u22120.255,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.038).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Plasma NRG1 concentration is increased in AD patients and correlates with CSF core AD and synaptic biomarkers and cognitive status. Thus, plasma NRG1 is a promising non-invasive biomarker to monitor synaptic impairment in AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-022-01014-7","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T04:02:48Z","timestamp":1653278568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Plasma neuregulin 1 as a synaptic biomarker in Alzheimer\u2019s disease: a discovery cohort study"],"prefix":"10.1186","volume":"14","author":[{"given":"Agathe","family":"Vrillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Mouton-Liger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Martinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Cognat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hourregue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Dumurgier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Bouaziz-Amar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Brinkmalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Hugon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Paquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"issue":"5594","key":"1014_CR1","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1126\/science.1074069","volume":"298","author":"DJ Selkoe","year":"2002","unstructured":"Selkoe DJ. Alzheimer\u2019s disease is a synaptic failure. Science. 2002;298(5594):789\u201391.","journal-title":"Science"},{"issue":"1","key":"1014_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00401-009-0536-x","volume":"118","author":"T Arendt","year":"2009","unstructured":"Arendt T. Synaptic degeneration in Alzheimer\u2019s disease. Acta Neuropathol. 2009;118(1):167\u201379.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"1014_CR3","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: correlation with cognitive severity. Ann Neurol. 1990;27(5):457\u201364.","journal-title":"Ann Neurol"},{"issue":"4","key":"1014_CR4","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572\u201380.","journal-title":"Ann Neurol"},{"issue":"2","key":"1014_CR5","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s00259-019-04461-x","volume":"47","author":"C Bastin","year":"2020","unstructured":"Bastin C, Bahri MA, Meyer F, Manard M, Delhaye E, Plenevaux A, et al. In vivo imaging of synaptic loss in Alzheimer\u2019s disease with [18F]UCB-H positron emission tomography. Eur J Nucl Med Mol Imaging. 2020;47(2):390\u2013402.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"1014_CR6","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1001\/jamaneurol.2018.1836","volume":"75","author":"M-K Chen","year":"2018","unstructured":"Chen M-K, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin S-F, et al. Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging. JAMA Neurol. 2018;75(10):1215\u201324.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1014_CR7","doi-asserted-by":"crossref","first-page":"e12179","DOI":"10.1002\/dad2.12179","volume":"13","author":"J Nilsson","year":"2021","unstructured":"Nilsson J, Gobom J, Sj\u00f6din S, Brinkmalm G, Ashton NJ, Svensson J, et al. Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer\u2019s disease. Alzheimers Dement (Amst). 2021;13(1):e12179.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"3","key":"1014_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00401-018-1851-x","volume":"136","author":"E Portelius","year":"2018","unstructured":"Portelius E, Olsson B, H\u00f6glund K, Cullen NC, Kvartsberg H, Andreasson U, et al. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol. 2018;136(3):363\u201376.","journal-title":"Acta Neuropathol"},{"key":"1014_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1750-1326-9-53","volume":"9","author":"A Brinkmalm","year":"2014","unstructured":"Brinkmalm A, Brinkmalm G, Honer WG, Fr\u00f6lich L, Hausner L, Minthon L, et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer\u2019s disease. Mol Neurodegener. 2014;9:53.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"1014_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jalz.2018.08.006","volume":"15","author":"\u00c5 Sandelius","year":"2019","unstructured":"Sandelius \u00c5, Portelius E, K\u00e4ll\u00e9n \u00c5, Zetterberg H, Rot U, Olsson B, et al. Elevated CSF GAP-43 is Alzheimer\u2019s disease specific and associated with tau and amyloid pathology. Alzheimers Dement. 2019;15(1):55\u201364.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"1014_CR11","doi-asserted-by":"publisher","first-page":"e953","DOI":"10.1212\/WNL.0000000000010131","volume":"95","author":"M Tible","year":"2020","unstructured":"Tible M, Sandelius \u00c5, H\u00f6glund K, Brinkmalm A, Cognat E, Dumurgier J, et al. Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease. Neurology. 2020;95(8):e953\u201361.","journal-title":"Neurology"},{"key":"1014_CR12","doi-asserted-by":"publisher","unstructured":"Mil\u00e0-Alom\u00e0 M, Brinkmalm A, Ashton NJ, Kvartsberg H, Shekari M, Operto G, et al. CSF synaptic biomarkers in the preclinical stage of Alzheimer disease and their association with MRI and PET: a cross-sectional study. Neurology. 2021. https:\/\/doi.org\/10.1212\/WNL.0000000000012853.","DOI":"10.1212\/WNL.0000000000012853"},{"key":"1014_CR13","doi-asserted-by":"publisher","first-page":"117727192095031","DOI":"10.1177\/1177271920950319","volume":"15","author":"E Camporesi","year":"2020","unstructured":"Camporesi E, Nilsson J, Brinkmalm A, Becker B, Ashton NJ, Blennow K, et al. Fluid biomarkers for synaptic dysfunction and loss. Biomark Insights. 2020;15:1177271920950319.","journal-title":"Biomark Insights"},{"issue":"3","key":"1014_CR14","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1021\/acs.jproteome.9b00824","volume":"19","author":"P Oeckl","year":"2020","unstructured":"Oeckl P, Halbgebauer S, Anderl-Straub S, von Arnim CAF, Diehl-Schmid J, Froelich L, et al. Targeted mass spectrometry suggests beta-synuclein as synaptic blood marker in Alzheimer\u2019s disease. J Proteome Res. 2020;19(3):1310\u20138.","journal-title":"J Proteome Res"},{"issue":"6555","key":"1014_CR15","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/378386a0","volume":"378","author":"D Meyer","year":"1995","unstructured":"Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature. 1995;378(6555):386\u201390.","journal-title":"Nature"},{"issue":"1","key":"1014_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0896-6273(00)80873-9","volume":"25","author":"D Wolpowitz","year":"2000","unstructured":"Wolpowitz D, Mason TB, Dietrich P, Mendelsohn M, Talmage DA, Role LW. Cysteine-rich domain isoforms of the neuregulin-1 gene are required for maintenance of peripheral synapses. Neuron. 2000;25(1):79\u201391.","journal-title":"Neuron"},{"issue":"3","key":"1014_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/cercor\/13.3.252","volume":"13","author":"H-J Yau","year":"2003","unstructured":"Yau H-J, Wang H-F, Lai C, Liu F-C. Neural development of the neuregulin receptor ErbB4 in the cerebral cortex and the hippocampus: preferential expression by interneurons tangentially migrating from the ganglionic eminences. Cereb Cortex. 2003;13(3):252\u201364.","journal-title":"Cereb Cortex"},{"issue":"27","key":"1014_CR18","doi-asserted-by":"publisher","first-page":"23967","DOI":"10.1074\/jbc.M111.251538","volume":"286","author":"X Luo","year":"2011","unstructured":"Luo X, Prior M, He W, Hu X, Tang X, Shen W, et al. Cleavage of neuregulin-1 by BACE1 or ADAM10 protein produces differential effects on myelination. J Biol Chem. 2011;286(27):23967\u201374.","journal-title":"J Biol Chem"},{"issue":"18","key":"1014_CR19","doi-asserted-by":"publisher","first-page":"7856","DOI":"10.1523\/JNEUROSCI.3372-12.2013","volume":"33","author":"D Fleck","year":"2013","unstructured":"Fleck D, van Bebber F, Colombo A, Galante C, Schwenk BM, Rabe L, et al. Dual cleavage of neuregulin 1 type III by BACE1 and ADAM17 liberates its EGF-like domain and allows paracrine signaling. J Neurosci. 2013;33(18):7856\u201369.","journal-title":"J Neurosci"},{"issue":"1","key":"1014_CR20","doi-asserted-by":"publisher","first-page":"28873","DOI":"10.1038\/srep28873","volume":"6","author":"A Kamezaki","year":"2016","unstructured":"Kamezaki A, Sato F, Aoki K, Asakawa K, Kawakami K, Matsuzaki F, et al. Visualization of Neuregulin 1 ectodomain shedding reveals its local processing in vitro and in vivo. Sci Rep. 2016;6(1):28873 Available from: https:\/\/www.nature.com\/articles\/srep28873. Cited 2021 Nov 6.","journal-title":"Sci Rep"},{"issue":"2","key":"1014_CR21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.5115\/acb.2011.44.2.116","volume":"44","author":"R-S Woo","year":"2011","unstructured":"Woo R-S, Lee J-H, Yu H-N, Song D-Y, Baik T-K. Expression of ErbB4 in the neurons of Alzheimer\u2019s disease brain and APP\/PS1 mice, a model of Alzheimer\u2019s disease. Anat Cell Biol. 2011;44(2):116\u201327.","journal-title":"Anat Cell Biol"},{"issue":"1","key":"1014_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/jnen\/62.1.42","volume":"62","author":"AR Chaudhury","year":"2003","unstructured":"Chaudhury AR, Gerecke KM, Wyss JM, Morgan DG, Gordon MN, Carroll SL. Neuregulin-1 and erbB4 immunoreactivity is associated with neuritic plaques in Alzheimer disease brain and in a transgenic model of Alzheimer disease. J Neuropathol Exp Neurol. 2003;62(1):42\u201354.","journal-title":"J Neuropathol Exp Neurol"},{"key":"1014_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2008.12.047","volume":"1258","author":"MS Pankonin","year":"2009","unstructured":"Pankonin MS, Sohi J, Kamholz J, Loeb JA. Differential distribution of neuregulin in human brain and spinal fluid. Brain Res. 2009;1258:1\u201311.","journal-title":"Brain Res"},{"issue":"1","key":"1014_CR24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13195-020-00655-w","volume":"12","author":"F Mouton-Liger","year":"2020","unstructured":"Mouton-Liger F, Dumurgier J, Cognat E, Hourregue C, Zetterberg H, Vanderstichele H, et al. CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12(1):88.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"1014_CR25","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1014_CR26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"Pt 9","key":"1014_CR27","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456\u201377.","journal-title":"Brain"},{"issue":"17","key":"1014_CR28","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","volume":"94","author":"IG McKeith","year":"2020","unstructured":"McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94(17):743\u201355.","journal-title":"Neurology"},{"issue":"3","key":"1014_CR29","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/WAD.0000000000000034","volume":"28","author":"P Sachdev","year":"2014","unstructured":"Sachdev P, Kalaria R, O\u2019Brien J, Skoog I, Alladi S, Black SE, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206\u201318.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1014_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.neulet.2014.12.024","volume":"587","author":"Y Hama","year":"2015","unstructured":"Hama Y, Yabe I, Wakabayashi K, Kano T, Hirotani M, Iwakura Y, et al. Level of plasma neuregulin-1 SMDF is reduced in patients with idiopathic Parkinson\u2019s disease. Neurosci Lett. 2015;587:17\u201321 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394014009690. Cited 2020 Mar 12.","journal-title":"Neurosci Lett"},{"key":"1014_CR31","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.neulet.2015.09.010","volume":"606","author":"R Wang","year":"2015","unstructured":"Wang R, Wang Y, Hu R, Chen X, Song M, Wang X. Decreased plasma levels of neureglin-1 in drug na\u00efve patients and chronic patients with schizophrenia. Neurosci Lett. 2015;606:220\u20134.","journal-title":"Neurosci Lett"},{"issue":"5","key":"1014_CR32","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/(SICI)1097-4547(20000301)59:5<612::AID-JNR4>3.0.CO;2-V","volume":"59","author":"M Ozaki","year":"2000","unstructured":"Ozaki M, Tohyama K, Kishida H, Buonanno A, Yano R, Hashikawa T. Roles of neuregulin in synaptogenesis between mossy fibers and cerebellar granule cells. J Neurosci Res. 2000;59(5):612\u201323.","journal-title":"J Neurosci Res"},{"issue":"1","key":"1014_CR33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.neuroscience.2004.04.026","volume":"127","author":"AJ Law","year":"2004","unstructured":"Law AJ, Shannon Weickert C, Hyde TM, Kleinman JE, Harrison PJ. Neuregulin-1 (NRG-1) mRNA and protein in the adult human brain. Neuroscience. 2004;127(1):125\u201336.","journal-title":"Neuroscience"},{"issue":"4","key":"1014_CR34","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.neuron.2007.03.028","volume":"54","author":"B Li","year":"2007","unstructured":"Li B, Woo R-S, Mei L, Malinow R. ErbB4, a receptor of the schizophrenia-linked protein neuregulin-1, controls glutamatergic synapse maturation and plasticity. Neuron. 2007;54(4):583\u201397 Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2031848\/. Cited 2021 Nov 6.","journal-title":"Neuron"},{"key":"1014_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuint.2016.04.012","volume":"97","author":"K-A Chang","year":"2016","unstructured":"Chang K-A, Shin KY, Nam E, Lee Y-B, Moon C, Suh Y-H, et al. Plasma soluble neuregulin-1 as a diagnostic biomarker for Alzheimer\u2019s disease. Neurochem Int. 2016;97:1\u20137.","journal-title":"Neurochem Int"},{"issue":"5","key":"1014_CR36","doi-asserted-by":"publisher","first-page":"E506","DOI":"10.1503\/jpn.200166","volume":"46","author":"J Duan","year":"2021","unstructured":"Duan J, Wei Y, Womer FY, Zhang X, Chang M, Zhu Y, et al. Neurobiological substrates of major psychiatry disorders: transdiagnostic associations between white matter abnormalities, neuregulin 1 and clinical manifestation. J Psychiatry Neurosci. 2021;46(5):E506\u201315 Available from: https:\/\/www.jpn.ca\/content\/46\/5\/E506. Cited 2021 Sep 28.","journal-title":"J Psychiatry Neurosci"},{"issue":"1","key":"1014_CR37","first-page":"024","volume":"4","author":"JC Cespedes","year":"2018","unstructured":"Cespedes JC, Liu M, Harbuzariu A, Nti A, Onyekaba J, Cespedes HW, et al. Neuregulin in health and disease. Int J Brain Disord Treat. 2018;4(1):024 Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6483402\/. Cited 2021 Nov 6.","journal-title":"Int J Brain Disord Treat"},{"key":"1014_CR38","first-page":"6683747","volume":"2020","author":"X Wang","year":"2020","unstructured":"Wang X, Zhang F, Ma W, Feng D, Zhang J, Xu J. Increased levels of serum neuregulin 1 associated with cognitive impairment in vascular dementia. Biomed Res Int. 2020;2020:6683747.","journal-title":"Biomed Res Int"},{"key":"1014_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.neurobiolaging.2021.08.002","volume":"108","author":"EAJ Willemse","year":"2021","unstructured":"Willemse EAJ, Sieben A, Somers C, Vermeiren Y, De Roeck N, Timmers M, et al. Neurogranin as biomarker in CSF is non-specific to Alzheimer\u2019s disease dementia. Neurobiol Aging. 2021;108:99\u2013109 Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0197458021002542. Cited 2021 Sep 30.","journal-title":"Neurobiol Aging"},{"issue":"10","key":"1014_CR40","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1002\/jnr.22392","volume":"88","author":"R Clare","year":"2010","unstructured":"Clare R, King VG, Wirenfeldt M, Vinters HV. Synapse loss in dementias. J Neurosci Res. 2010;88(10):2083\u201390 Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3068914\/. Cited 2021 Sep 30.","journal-title":"J Neurosci Res"},{"issue":"4","key":"1014_CR41","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.bcp.2013.12.028","volume":"88","author":"SW Scheff","year":"2014","unstructured":"Scheff SW, Neltner JH, Nelson PT. Is synaptic loss a unique hallmark of Alzheimer\u2019s disease? Biochem Pharmacol. 2014;88(4):517\u201328 Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4230706\/. Cited 2021 Sep 30.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"1014_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.neuron.2014.06.007","volume":"83","author":"L Mei","year":"2014","unstructured":"Mei L, Nave K-A. Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases. Neuron. 2014;83(1):27\u201349.","journal-title":"Neuron"},{"issue":"4","key":"1014_CR43","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.neuron.2007.04.009","volume":"54","author":"R-S Woo","year":"2007","unstructured":"Woo R-S, Li X-M, Tao Y, Carpenter-Hyland E, Huang YZ, Weber J, et al. Neuregulin-1 enhances depolarization-induced GABA release. Neuron. 2007;54(4):599\u2013610.","journal-title":"Neuron"},{"issue":"2","key":"1014_CR44","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0896-6273(00)81176-9","volume":"26","author":"YZ Huang","year":"2000","unstructured":"Huang YZ, Won S, Ali DW, Wang Q, Tanowitz M, Du QS, et al. Regulation of neuregulin signaling by PSD-95 interacting with ErbB4 at CNS synapses. Neuron. 2000;26(2):443\u201355.","journal-title":"Neuron"},{"issue":"2","key":"1014_CR45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/WNR.0b013e3282f3da10","volume":"19","author":"GM Pitcher","year":"2008","unstructured":"Pitcher GM, Beggs S, Woo R-S, Mei L, Salter MW. ErbB4 is a suppressor of long-term potentiation in the adult hippocampus. Neuroreport. 2008;19(2):139\u201343.","journal-title":"Neuroreport"},{"issue":"41","key":"1014_CR46","doi-asserted-by":"publisher","first-page":"9378","DOI":"10.1523\/JNEUROSCI.2100-05.2005","volume":"25","author":"O-B Kwon","year":"2005","unstructured":"Kwon O-B, Longart M, Vullhorst D, Hoffman DA, Buonanno A. Neuregulin-1 reverses long-term potentiation at CA1 hippocampal synapses. J Neurosci. 2005;25(41):9378\u201383.","journal-title":"J Neurosci"},{"issue":"20","key":"1014_CR47","doi-asserted-by":"publisher","first-page":"4974","DOI":"10.1523\/JNEUROSCI.1086-05.2005","volume":"25","author":"Z Gu","year":"2005","unstructured":"Gu Z, Jiang Q, Fu AKY, Ip NY, Yan Z. Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex. J Neurosci. 2005;25(20):4974\u201384.","journal-title":"J Neurosci"},{"issue":"3","key":"1014_CR48","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S0306-4522(03)00503-7","volume":"121","author":"S Roysommuti","year":"2003","unstructured":"Roysommuti S, Carroll SL, Wyss JM. Neuregulin-1beta modulates in vivo entorhinal-hippocampal synaptic transmission in adult rats. Neuroscience. 2003;121(3):779\u201385.","journal-title":"Neuroscience"},{"issue":"6661","key":"1014_CR49","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/37795","volume":"390","author":"M Ozaki","year":"1997","unstructured":"Ozaki M, Sasner M, Yano R, Lu HS, Buonanno A. Neuregulin-beta induces expression of an NMDA-receptor subunit. Nature. 1997;390(6661):691\u20134.","journal-title":"Nature"},{"issue":"15","key":"1014_CR50","doi-asserted-by":"publisher","first-page":"5660","DOI":"10.1523\/JNEUROSCI.21-15-05660.2001","volume":"21","author":"Y Liu","year":"2001","unstructured":"Liu Y, Ford B, Mann MA, Fischbach GD. Neuregulins increase alpha7 nicotinic acetylcholine receptors and enhance excitatory synaptic transmission in GABAergic interneurons of the hippocampus. J Neurosci. 2001;21(15):5660\u20139.","journal-title":"J Neurosci"},{"issue":"4","key":"1014_CR51","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1086\/342734","volume":"71","author":"H Stefansson","year":"2002","unstructured":"Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002;71(4):877\u201392 Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC378543\/. Cited 2021 Sep 30.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"1014_CR52","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrn2392","volume":"9","author":"L Mei","year":"2008","unstructured":"Mei L, Xiong W-C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci. 2008;9(6):437\u201352.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"1014_CR53","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neuroscience.2007.03.051","volume":"147","author":"CMP O\u2019Tuathaigh","year":"2007","unstructured":"O\u2019Tuathaigh CMP, Babovic D, O\u2019Sullivan GJ, Clifford JJ, Tighe O, Croke DT, et al. Phenotypic characterization of spatial cognition and social behavior in mice with \u201cknockout\u201d of the schizophrenia risk gene neuregulin 1. Neuroscience. 2007;147(1):18\u201327.","journal-title":"Neuroscience"},{"issue":"4","key":"1014_CR54","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.celrep.2014.07.026","volume":"8","author":"A Agarwal","year":"2014","unstructured":"Agarwal A, Zhang M, Trembak-Duff I, Unterbarnscheidt T, Radyushkin K, Dibaj P, et al. Dysregulated expression of neuregulin-1 by cortical pyramidal neurons disrupts synaptic plasticity. Cell Rep. 2014;8(4):1130\u201345 Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S221112471400610X. Cited 2020 Dec 6.","journal-title":"Cell Rep"},{"issue":"1","key":"1014_CR55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/nm0103-3","volume":"9","author":"L-B Yang","year":"2003","unstructured":"Yang L-B, Lindholm K, Yan R, Citron M, Xia W, Yang X-L, et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med. 2003;9(1):3\u20134.","journal-title":"Nat Med"},{"key":"1014_CR56","doi-asserted-by":"publisher","first-page":"104622","DOI":"10.1016\/j.yexmp.2021.104622","volume":"120","author":"J-Y Yoo","year":"2021","unstructured":"Yoo J-Y, Kim H-B, Baik T-K, Lee J-H, Woo R-S. Neuregulin 1\/ErbB4\/Akt signaling attenuates cytotoxicity mediated by the APP-CT31 fragment of amyloid precursor protein. Exp Mol Pathol. 2021;120:104622.","journal-title":"Exp Mol Pathol"},{"key":"1014_CR57","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.nbd.2017.07.001","volume":"106","author":"H Zhang","year":"2017","unstructured":"Zhang H, Zhang L, Zhou D, He X, Wang D, Pan H, et al. Ablating ErbB4 in PV neurons attenuates synaptic and cognitive deficits in an animal model of Alzheimer\u2019s disease. Neurobiol Dis. 2017;106:171\u201380.","journal-title":"Neurobiol Dis"},{"issue":"6","key":"1014_CR58","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/j.1471-4159.2004.02817.x","volume":"91","author":"L Zhang","year":"2004","unstructured":"Zhang L, Fletcher-Turner A, Marchionni MA, Apparsundaram S, Lundgren KH, Yurek DM, et al. Neurotrophic and neuroprotective effects of the neuregulin glial growth factor-2 on dopaminergic neurons in rat primary midbrain cultures. J Neurochem. 2004;91(6):1358\u201368.","journal-title":"J Neurochem"},{"issue":"2","key":"1014_CR59","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/ijms22020698","volume":"22","author":"HJ Seo","year":"2021","unstructured":"Seo HJ, Park JE, Choi S-M, Kim T, Cho SH, Lee K-H, et al. Inhibitory neural network\u2019s impairments at hippocampal CA1 LTP in an aged transgenic mouse model of Alzheimer\u2019s disease. Int J Mol Sci. 2021;22(2):698.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1014_CR60","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 2021;141(5):709\u201324.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"1014_CR61","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422\u201333.","journal-title":"Lancet Neurol"},{"key":"1014_CR62","doi-asserted-by":"crossref","unstructured":"Ashton N, Janelidze S, Khleifat AA, Leuzy A, van der Ende E, Karikari T, et al. Diagnostic value of plasma neurofilament light: a multicentre validation study. Review. 2020; Available from: https:\/\/www.researchsquare.com\/article\/rs-63386\/v1. Cited 2021 May 19.","DOI":"10.21203\/rs.3.rs-63386\/v1"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01014-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-01014-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01014-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T20:37:22Z","timestamp":1700599042000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-01014-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1014"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-01014-7","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]},"assertion":[{"value":"29 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Bichat Hospital Ethics Committee of Paris Diderot University (N\u00b010\u2013037, 18\/03\/2010) and all the participants have given their written consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KB has served as a consultant or at advisory boards for Abcam, Axon, Biogen, JOMDD\/Shimadzu, Lilly, MagQu, Prothena, Roche Diagnostics, and Siemens Healthineers, and as data monitoring committee for Julius Clinical and Novartis. KB is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures. HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. CP is a member of the International Advisory Boards of Lilly; is a consultant for Fujirebio, Alzhois, Euroimmune, Ads Neuroscience, Roche, AgenT, and Gilead; and is involved as an investigator in several clinical trials for Roche, Esai, Lilly, Biogen, Astra-Zeneca, Lundbeck, and Neuroimmune. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}